Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001079973-25-000869
Filing Date
2025-05-15
Accepted
2025-05-15 19:21:07
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6393
  Complete submission text file 0001079973-25-000869.txt   8281
Mailing Address 161A SHEDDEN ROAD ONE ARTILLERY COURT P.O. BOX 10085 GRAND CAYMAN E9 KY1-1001
Business Address 161A SHEDDEN ROAD ONE ARTILLERY COURT P.O. BOX 10085 GRAND CAYMAN E9 KY1-1001 646-688-5654
L1 Capital Global Opportunities Master Fund, Ltd. (Filed by) CIK: 0001702202 (see all company filings)

EIN.: 981241877 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Subject) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92271 | Film No.: 25956528
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)